Veeva Systems Inc.

Veeva Systems (VEEV) Reiterated Confidence in Achieving Its 2030 Financial Targets

TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy returned -3.55% (gross) and -3.76% (net) in the fourth quarter compared to a -3.70% return for the Russell Midcap Growth Index. In 2025, the strategy returned 14.84%

Source: Insider Monkey Mar 20, 2026

A Look At Veeva Systems (VEEV) Valuation After New AOP Health Cloud Adoption Win

Veeva Systems (VEEV) is back in focus after AOP Health chose its Development, Quality, Commercial, and Data Clouds to run integrated rare disease and intensive care programs, connecting research with commercialization. See our latest analysis for Veeva Systems. The AOP Health win comes at a time when Veeva’s recent 7 day share price return of 2.66% and 30 day share price return of 4.96% contrast with a 1 year total shareholder return decline of 21.31%. This suggests that short term momentum...

Source: Simply Wall St. Mar 20, 2026

Is Veeva Systems (VEEV) A Good Stock To Buy Now?

Is VEEV a good stock to buy? We came across a bullish thesis on Veeva Systems Inc. on LongTermValue Research’s Substack. In this article, we will summarize the bulls’ thesis on VEEV. Veeva Systems Inc.’s share was trading at $185.28 as of March 16th. VEEV’s trailing and forward P/E were 34.06 and 20.92 respectively according to Yahoo Finance.

Source: Insider Monkey Mar 17, 2026

Veeva Systems (VEEV) Just Overtook the 20-Day Moving Average

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Source: Zacks Mar 17, 2026

How Much Upside is Left in Veeva (VEEV)? Wall Street Analysts Think 52.1%

The average of price targets set by Wall Street analysts indicates a potential upside of 52.1% in Veeva (VEEV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Source: Zacks Mar 16, 2026

Tempus AI Advances Clinical Applications and Healthcare Software

TEM expands its clinical software push with TIME trial-matching, Tempus Next care intelligence and an upgraded Tempus One AI assistant for providers.

Source: Zacks Mar 16, 2026